The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by Bristol-Myers Squibb ( NYSE: BMY ), as a novel treatment for adults with the psychiatric disorder schizophrenia.
Bristol-Myers ( BMY ) traded ~ 5% higher in.
